Posted byOrthoEx Posted in
Posted on May 14, 2018

CAESAREA, IsraelMay 14, 2018 /PRNewswire/ — Mazor Robotics Ltd. (TASE: MZOR) (NASDAQ-GM: MZOR), a pioneer and a leader in the field of robotic guidance systems, reported record first quarter revenue of $15.5 million compared to $11.7 million in the first quarter of 2017.

“Our record first quarter revenue reflects clinical adoption, as we surpassed 33,000 cases performed, and the continued global demand for the Mazor X and Renaissance systems,” commented Ori Hadomi, Chief Executive Officer. “Commercially, we successfully expanded into a new international market with the Mazor X and making progress penetrating into the Ambulatory Surgery Center (“ASC”) market in the U.S. with the Renaissance.  Our performance, coupled with the growing number of peer-reviewed papers, presentations and the interim data from our prospective studies, is transforming spine surgery in markets around the world.  Finally, we are also advancing and expanding our technology development efforts with Medtronic, and I am pleased to share that commercialization of the Mazor X platform, which integrates Medtronic’s Stealth navigation and offers a unique robot-guided implant solution that eliminates the need for guidewires, is expected at the end of 2018.”


Revenue for the three months ended March 31, 2018 increased 32% to $15.5 million compared to $11.7 million in the year-ago first quarter, mainly due to increased recurring revenue from kit sales, services and other.  U.S. revenue increased 27% to $14.2 million compared to $11.2 million in the year-ago first quarter. International revenue increased 160% to $1.3 million compared to $0.5 million in the year-ago first quarter.

The Company’s gross margin for the three months ended March 31, 2018 was 58.3% compared to 64.6% in the year-ago first quarter.  This expected decrease is attributed mainly to the pricing terms with Medtronic. Total operating expenses were $10.5 million compared to $13.3 million in the year-ago first quarter, mainly due to lower selling and marketing expenses, following the transition to the global distribution phase of the Medtronic partnership.  Operating loss was $1.4 million compared to an operating loss of $5.7 million in the year-ago first quarter. Net loss for the first quarter of 2018 was $1.3 million, or $0.02 per share, compared to a net loss of $5.2 million, or $0.11 per share, for the year-ago first quarter.

Cash provided by operating activities was $2.7 million compared to cash provided by operating activities of $0.7 millionin last year’s first quarter as a result of high collection efforts from customers. As of March 31, 2018, cash, cash equivalents and investments totaled $114.5 million.


The tables below include reconciliations of the Company’s GAAP results to non-GAAP results. The reconciliations relate to non-cash expenses in the amount of $1.6 million with respect to share-based payments and amortization of intangible assets recorded in the first quarter of 2018. On a non-GAAP basis, the net income in the first quarter of 2018 was $0.3 million, or $0.01 per share, compared to net loss of $3.9 million, or $0.08 per share, for the year-ago first quarter.


The company will host a conference call to discuss these results on Monday, May 14, 2018, at 8:30 AM EDT (3:30 PM IDT).  Investors within the United States interested in participating are invited to call 800-239-9838.   Participants in Israel can use the toll-free dial-in number 1809 212 883. All other international participants can use the dial-in number +1 323-794-2551.

A replay of the event will be available for two weeks following the conclusion of the call. To access the replay, callers in the United States can call 1-888-203-1112 and reference the Replay Access Code: 3873868. All international callers can dial +1 719-457-0820, using the same Replay Access Code. To access the webcast, please visit www.mazorrobotics.comand select ‘Investor Relations.’

Use of Non-GAAP Measures

In addition to disclosing financial results calculated in accordance with generally accepted accounting principles in conformity with International Financial Reporting Standards (GAAP), this press release contains Non-GAAP financial measures for gross profit, operating expenses, operating profit (loss), net income (loss) and basic and diluted earnings (loss) per share that exclude the effects of non-cash expense of amortization of intangible assets and share-based payments. Management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the Company’s performance that enhances management’s and investors’ ability to evaluate the Company’s net income (loss) and earnings (loss) per share and to compare them to historical net income (loss) and earnings (loss) per share.

The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Management uses both GAAP and non-GAAP measures when operating and evaluating the Company’s business internally and therefore decided to make these non-GAAP adjustments available to investors.

About Mazor

Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary technologies and products aimed at redefining the gold standard of quality care. Mazor Robotics Guidance System enables surgeons to conduct spine and brain procedures in an accurate and secure manner. For more information, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding interim data from prospective studies, advancing and expanding technology development efforts, timing of integration of Stealth navigation, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F filed with the SEC on April 30, 2018 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.

Mazor Robotics Ltd.


(U.S. Dollars in thousands, except per share data)

Three month period

ended March 31,










Cost of revenue





Gross profit





Operating costs and expenses:

Research and development, net





Selling and marketing





General and administrative





Total operating costs and expenses





Loss from operations





Financing income, net





Loss before taxes on income





Income tax expense (benefit)





Net loss





Net loss per share – Basic and diluted





Weighted average common shares
outstanding – Basic and diluted